Aly-Khan A. Lalani

Oct 14, 2024 | acsjournals.onlinelibrary.wiley.com | Ahmad Mousa |David-Dan Nguyen |Aly-Khan A. Lalani |Raj Satkunasivam

INTRODUCTION Androgen-deprivation therapy (ADT) remains a mainstay in the management of patients with locally advanced and metastatic prostate cancer. Patients on ADT are increasingly exposed to a longer duration of prostate cancer therapy, which can lead to long-term toxicity and morbidity and can increase other-cause mortality.

Jan 29, 2024 | europeanurology.com | Kosuke Takemura |Matthew Ernst |J. Connor Wells |Audreylie Lemelin |Renee Maria Saliby |Talal El Zarif | +10 more

AbstractPatients with brain metastases (BrM) from renal cell carcinoma and their outcomes are not well characterized owing to frequent exclusion of this population from clinical trials. We analyzed data for patients with or without BrM using the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). A total of 389/4799 patients (8.1%) had BrM on initiation of systemic therapy.